Get started
Aytu BioPharma, Inc.Aytu BioPharma, Inc.Aytu BioPharma, Inc.

Aytu BioPharma, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

AYTU trade ideas

AYTU | Aytu Bio Pharma, Inc. Healthcare | US Stocks NASDAQ📈 Technical Chart Patterns & Trend Analysis 📉 Identifying potential trading opportunities based on trend analysis: bullish divergence can be seen oh daily time frame and aslo a double bottom indicating a trend reversal. BUY STOP will be good option in this scenario . 📊 Technical analysis helps identify potential entry and exit points for trades. Remember to use appropriate risk management strategies and conduct further analysis before making trading decisions. Happy trading! 💹"
NASDAQ:AYTU
by shah_baz
Aytu BioPharma (USA: $AYTU) Trading For Less Than $1 Dollar! 🧬Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
NASDAQ:AYTULong
by DEXWireNews
1
AYTU All Time Low | Fast Track Designation form FDA todayAYTU Aytu BioPharma announced today that the FDA has granted Fast Track designation to AR101, a protein kinase inhibitor, for the treatment of patients with Vascular Ehlers-Danlos Syndrome. After the bullish news, AYTU stock hit the all time low level. 52 Week Range 0.76 - 7.20 LADENBURG THALM has a price target of $14.50 for the stock. I think a reversal is imminent. My price target is $5.25. Looking forward to read your opinion about it.
NASDAQ:AYTULong
by TopgOptions
1
HEALIGHT PATENT approval 11/23The most bearish of tickers but things change... sometimes very quickly The HL device will have a huge impact in reducing the length of hospital stays due to VAP and other respiratory illnesses as well as a number of benefits for its outpatient potential. Hint: when hospitals and insurance companies can save billions of dollars of the tech, especially when world wide respiratory illness is the biggest problem, BIG BIG POTENTIAL! The data behind the Healight Device is exceptional and there's one reason this has been brought down so brutally: CEDAR SINAI does not have the technology patented yet. That changes on 11/23/21 when the patent will be officially issued. The Data.... You really gotta dig in and review it because AYTU sure is tight lipped about it. But the technology is very impressive. Cedar Sinai confidentiality agreement? Very likely Bag holder central and a gold mine for shorts the past year? ABSOLUTELY! I can't blame it all on the CEO's inability to create shareholder value or the hedge Armistice capital LLC for.... well, playing Armistice with the SP, keeping it from delisting or letting the SP get out of hand before Cedars invests. Because Cedars will invest.... when the patent is issued in their name Its a likely requirement of the company upon acquiring the licensing rights for respiratory illnesses to the HL device to do two things: 1: get everything inline and ready 2: Keep the SP inline with the timeline without it getting delisted or being too expensive (enter Armistice an agreement made by opposing sides in a war to stop fighting for a certain time; a truce) As of now AYTU is already undervalued, even with its mediocre pipeline. but were here for Healight. ER 11/15 probably wont do much but if it does pop, dont expect much besides an offering. GL
NASDAQ:AYTU
by GrowerNottaShowER
AYTU BioPharma (NASDAQ: $AYTU) Oversold & Ready To Reverse 🧬Aytu BioPharma: Helping children get off to a healthier start and a better life. Aytu is committed to improving the health of all children. We’re developing a portfolio of products to help children be their best and now expanding into ADHD. Our Adult and consumer health products remain an important part of our heritage, while we study COVID-19 treatments and invest in breakthroughs for rare diseases. Follow us on our journey. A growing portfolio: ADHD PEDIATRICS ADULT HEALTH CONSUMER HEALTH
NASDAQ:AYTULong
by RedHotStocks
1
AYTU BioPharma (NASDAQ: $AYTU) Could See Massive Upside 🧪🧪🧪Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Englewood, Colorado.
NASDAQ:AYTULong
by Bullishcharts
2
AYTU Finally Waking Up?AYTU has been under pressure forever with the 50 DMA being the strongest level of resistance over the last few months. However, if you take the chart waaayyyyy out, you'll see that it's bouncing off of a historic level of support, which was confirmed after this latest move. Yet again the 50DMA denied the rally even with higher volume. The company has an upcoming presentation at the Raymond James Human Health Innovations Conference on June 23rd. "Since its inception, AYTU has evolved into an acquisition-based company that puts a priority on strategic in-licensing. It also has a strong drug development pipeline that focuses on rare genetic diseases called vascular Ehlers-Danlos Syndrome (vEDS). Currently, it’s testing a potential treatment – AR101/enzastaurin, in an attempt to reduce morbidity and lengthen life. While testing can take a substantial amount of time, having a steady flow of research in a pipeline is always encouraging for biotech investors to see." Quote Source: 7 Top Penny Stocks to Watch Right Now With Big News
NASDAQ:AYTU
by PennyStocks101
$AYTU entry PT 6.30-6.50 PT 11 and higherAytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Englewood, Colorado.
NASDAQ:AYTULong
by BADQOMOCAWGOWLD